Our research expertise spans cancer genomics, DNA damage, RNA biology, and drug development. We are also expanding our focus on drug delivery, particularly through nanotechnology-based methods for delivering small RNA mimics and inhibitors.
News
- Nature Communications: HELZ-BRCA2 complex resolves R-loops to drive transcription-coupled homologous recombination (Wasmuth, Zheng, Sung Lab, Zhao)
- International Journal of Molecular Sciences: Biogenic Metal Nanoparticles from Indian Flora as Programmable Bio-Interfaces: From Phytochemical Coronas to Precision Nanomedicine (Wasmuth Lab)
- Function: Constitutive mTORC1 Activation in Skeletal Muscle Increases Inflammation but is not Sufficient to Impair Glucose Tolerance (Lai Lab)
- Nature Communications: Multifaceted roles of PDS5B in RAD51-dependent homology-directed DNA repair and replication fork protection (Sung Lab, Libich, Olsen, Wasmuth, Rao, et al)
- Nature Structural & Molecular Biology: CST complex promotes second-strand synthesis in break-induced replication (Sung Lab, Malkova, et al)
Events
Greehey CCRI Seminar Series – Fall ’26: Jeanne Stachowiak, PhD (UT Austin)
Presentation title: Intrinsic Disorder as an Organizing Principle for Cellular Membranes
Greehey CCRI Spring ’26 Seminar Series: Reuben Harris, PhD (UTHSA)
Presentation title: “Progress on the development of novel drugs for viral proteases”
Greehey CCRI Seminar Series: Lingtao Jin, PhD (UTHSA)
Presentation title: “Kinase Signaling in Cancer Drug Resistance”